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ABSTRACT
Mutations in SPARTAN are associated with early
onset hepatocellular carcinoma and progeroid fea-
tures. A regulatory function of Spartan has been im-
plicated in DNA damage tolerance pathways such
as translesion synthesis, but the exact function of
the protein remained unclear. Here, we reveal the
role of human Spartan in facilitating replication of
DNA–protein crosslink-containing DNA. We found
that purified Spartan has a DNA-dependent protease
activity degrading certain proteins bound to DNA.
In concert, Spartan is required for direct DPC re-
moval in vivo; we also show that the protease Spar-
tan facilitates repair of formaldehyde-induced DNA–
protein crosslinks in later phases of replication us-
ing the bromodeoxyuridin (BrdU) comet assay. More-
over, DNA fibre assay indicates that formaldehyde-
induced replication stress dramatically decreases
the speed of replication fork movement in Spartan-
deficient cells, which accumulate in the G2/M cell cy-
cle phase. Finally, epistasis analysis mapped these
Spartan functions to the RAD6-RAD18 DNA dam-
age tolerance pathway. Our results reveal that Spar-
tan facilitates replication of DNA–protein crosslink-
containing DNA enzymatically, as a protease, which
may explain its role in preventing carcinogenesis and
aging.
INTRODUCTION
DNA is constantly exposed to different exogenous and en-
dogenous factors that cause DNA damage which, if left un-
repaired, challenges the movement of the replication ma-
chinery. Stalling of the replication fork can lead to strand
breaks and chromosomal rearrangements causing genome
instability, early onset of aging and eventually cancer (1–3).
To rescue the stalled replication fork, so-called DNA dam-
age tolerance (DDT) pathways have evolved; the name re-
flects the belief that these pathways do not necessarily re-
pair the actual lesion causing fork stalling but rather facil-
itate mechanisms that achieve replication across them such
as translesion synthesis and template switching (4–6). In-
deed, several types of DNA lesions do not require repair
processing for their bypass such as the UV-crosslinked cys-
synT-T dimers, which can be efficiently bypassed by transle-
sion synthesis polymerase  (7). However, there are lesions,
such as interstrand-crosslinks or protein–DNA crosslinks
(DPC), whose processing cannot be omitted before replica-
tion proceeds across them (8). DPCs are particularly chal-
lenging lesions due to their bulky size and sometimes hard-
to-displace DNA-binding property and because they can
inhibit the movement of not only polymerases but of the
replicative helicase as well (9,10). However, until recently,
replication-coupled DPC repair has not received particular
attention.
Events at the stalled replication machinery are regulated
by the damage-induced ubiquitylation of proliferating cell
nuclear antigen (PCNA) (the sliding clamp of the replica-
tive polymerase) performed predominantly by the Rad18
ubiquitin ligase (11,12). The so-called RAD6-RAD18DDT
pathway includes regulators such as other ubiquitin lig-
ases and effectors like translesion polymerases for direct
damage bypass as well as double-stranded DNA translo-
cases for template switching (13–16). Monoubiquitylated
PCNA can provide a binding platform for manyDDT play-
ers to exchange the replicative polymerase at the 3′-prime
end and thus facilitate replication through the lesion. For
example, the binding of translesion synthesis polymerases
to ubiquitylated PCNA enables their access to the lesion.
Monoubiquitin–PCNA can be further ubiquitylated; the
generated polyubiquitin–PCNA is required for template
switching––mediated by specialized dsDNA translocases
such as HLTF––during which the newly replicated nascent
strand of the sister duplex can serve as a template for DNA
synthesis (17,18). However, immediate replication through
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the damage is not always possible, and gaps may remain op-
posite the lesions, whichmight be filled in only after the ma-
jority of the DNA has been replicated in the late S or G2
phases; thus, this process is frequently referred to as post-
replication repair (19,20).
One of the puzzling questions is the decision making be-
tween various DDT pathways when the replication fork
stalls at lesions. At least some elements of the question
might be answered by studying Spartan (known also as
DVC1) identified by our and other laboratories as a pre-
viously unrecognized member of the DDT pathway (21–
26). Upon UV-induced DNA damage, Spartan is recruited
to the site of the stalled replication fork, facilitated by
its PCNA-interacting (PIP) and ubiquitin-binding (UBZ)
motifs, which ensure direct interaction with ubiquitylated
PCNA. Spartan increases the cellular level of ubiquity-
lated PCNA by either inhibiting USP1-dependent PCNA-
deubiquitylation or by stimulating the Rad18 ubiquitin lig-
ase and can facilitate the recruitment of translesion synthe-
sis polymerase  to the lesion (21,22,24). Other studies did
not find connection between Rad18-mediated PCNA ubiq-
uitylation and Spartan recruitment but observed that upon
binding to PCNA Spartan recruits the ubiquitin-selective
chaperone p97 to blocked forks, which may facilitate p97-
dependent removal of polymerase  from monoubiquity-
lated PCNA.Moreover, Spartanwas reported to directly in-
teract with POLD3, an accessory subunit of the replicative
polymerase , and contribute to the suppression of damage-
induced mutagenesis (24,27). Although the detailed func-
tion of Spartan in the regulation of PCNA ubiquitylation
and polymerase switch is not clear yet, all previous studies
point to a central role for Spartan in DDT (21,28,29). Its
function in protecting genome stability is also supported by
recent findings revealing that mutations in human SPAR-
TAN cause early onset hepatocellular carcinoma, genomic
instability and a progeroid feature known as Ruijs-Aalfs
syndrome (29,30). Furthermore, Spartan insufficiency in
mice causes chromosomal instability, cellular senescence
and early onset of age-related phenotypes, whereas com-
plete loss of SPARTAN results in early embryonic lethality
(28).
Yeast Wss1 was suggested to be a Spartan homologue
because the two proteins exhibit similar domain organiza-
tion containing a metalloprotease domain in the form of
an SprT domain in Spartan and a WLM domain in Wss1,
an SHP motif and Spartan harbours a ubiquitin-binding-
zinc-finger (UBZ) motif for ubiquitin binding while Wss1
has two SUMO-interacting motifs (31). Recent discovery
revealed that Wss1 exhibits a DNA-dependent protease ac-
tivity in degrading DPCs, and yeast genetic evidence pro-
vided strong support for its major role in eliminating DPCs
in connection with replication (32). Jentsch et al. also sug-
gested that Wss1 may be the first identified member of a so
far hidden repair pathway for direct proteolytic removal of
DNA-bound proteins and raised the possibility of the exis-
tence of this mechanism in higher eukaryotes as well (31–
33).
DPCs can be generated by exogenous reactive agents such
as reactive aldehydes, ionizing irradiation and UV light but
are also quite commonly formed during cellularmetabolism
due to either the trapping of a normally transient cova-
lent protein-DNA intermediate such as the topoisomerase-
DNA reaction or chemical reactions caused by reactive
aldehydes such as formaldehyde (FA), which can be gen-
erated in the course of histone demethylation or during
the metabolism of ethanol (34–36). Exposure to FA has
been reported to cause nasopharyngeal cancer and myeloid
leukaemia; consequently, FA was classified as a Class I hu-
man carcinogen by the IARC in 2006 (37).
DPCs present a high threat to cellular life since they
strongly inhibit transcription as well as replication, but, un-
til recently, no specific mechanism has been proposed for
their removal, and nucleotide excision repair and homolo-
gous recombination were believed to repair them (38). The
discovery of yeast Wss1 as a protease directly targeting
the protein component of DPCs has changed our thinking
about DPC repair. However, until now, no clear orthologue
of Wss1 has been described in higher eukaryotes, and the
most timely question of whether Spartan has a protease ac-
tivity and participates inDPC repair has not been answered.
Here, we provide biochemical evidence that human Spar-
tan is a DNA-dependent protease for the specific removal
of certain DNA-bound proteins. We also present in vivo
evidence for the role of Spartan in direct DPC removal
and replication of FA-induced DPCs by monitoring DPC-
content, comet-assay and DNA-fibre techniques. Finally,
we carried out epistasis analysis and mapped Spartan’s
function in the replication of DPC-containing DNA to the
RAD6-RAD18DDT pathway. Our study indicates the exis-
tence of a novel Spartan protease-based DPC-repair path-
way in human cells.
MATERIAL AND METHODS
Spartan cleavage assay
TAP purification of Spartan and Mgs1 and purifications
of the Fan1, HLTF, yRad5, Ub-PCNA, PCNA, RFC and
RPA proteins, used as potential substrates for the Spartan
protease, were carried out according to published proto-
cols (18,39). Wild-type and mutant Spartan proteins were
expressed in yeast, purified using Glutathione beads and
eluted either with glutathione or by cleavage between the
GST- and FLAG-Tags by the PreScission protease, re-
spectively, as described previously (21). Protease assays
were typically carried out in 10 l buffer containing 20
mM Tris/HCl, pH: 7.5, 50 mM NaCl and 0.5 g puri-
fied Spartan in the presence or absence of 1 g X174
single-stranded DNA. Reactions were incubated at 37◦C
for 2 h or as indicated otherwise in the figures, followed
by adding Laemmli buffer before SDS-PAGE and subse-
quent Coomassie blue staining or Western blotting with
anti-FLAG antibody against FLAG-Spartan. To test the
DNA dependence of Spartan’s protease activity, 1 g of
several types of DNA was added to the reaction: single-
stranded X174 virion, double-stranded nicked Bluescript
plasmid or its enzymatically nicked version, single-stranded
75-mer oligonucleotide and partial heteroduplex 75/45-mer
oligonucleotides.
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Cell cultures and Western blots
Human embryonic kidney HEK 293 cells were cultured
in Dulbecco’s Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Sigma) and antibi-
otics (100 g/ml streptomycin sulphate and 100 U/ml
penicillin) at 37◦C. Transfections were carried out using
the Lipofectamin 2000 (ThermoFischer Scientific) trans-
fection reagent, according to the manufacturer’s pro-
tocol. The level of ectopic expression was detected at
48 h after plasmid transfection by harvesting the cells
and performing Western blot analysis. For immunoblots,
mouse HRP-conjugated anti-FLAG antibody (Sigma, M2
A8592,1:3000) and for the detection of ectopic PCNA level
mouse HRP-conjugated anti-PCNA antibody (Santa Cruz
Biotechnology, sc-56 HRP, 1:3000) was used. For the detec-
tion of -actin expression level in Western blots, rabbit anti
-actin antibody (Abcam, 1:300) was used as primary and
HRP-conjugated goat anti-rabbit IgG antibody (DAKO, P
0448, 1:3000) was used as secondary antibody. To visualize
HRP-conjugated antibodies, the Western Bright ECL (Ad-
vansta, DV-K12045-D50) detection kit was used.
Generation of stably silenced cell lines
To generate cell lines with stable knockdown of SPAR-
TAN and SPARTAN/RAD18, HEK 293 WT cells were
transfected with plasmids containing specific shDNA
sequences: pIL2322 (containing SPARTAN shDNA):
O2689: 5′ AGCTTCTAC TTTCCTAGA GTATCATTC
AAGAGATGA TACTCTAGG AAAGTAGTT TTTTG
3′ and pIL2321 (carrying RAD18 shDNA): O2702:
5′-AGCTTGTTC AGACATCAT AAGAGATTC AA-
GAGATCT CTTATGATG TCTGAACTG TTTTTG
3′. Stably expressing cell lines were selected for G418
resistance.
Assay for monitoring in vivo DPC removal
Detection of DPCs was performed by the SDS/KCl precip-
itation assay (32,40) according to the patent of Costa et al.
(US patent number 5,545,529), which is an adaptation of
the SDS/KCl precipitation assay for human cells.
Briefly, exponentially growing cells were treated with 500
M formaldehyde in serum-free medium for 2 h, washed
with PBS and harvested (0 h time point) or left to recover
in complete DMEM for 3 h or 6 h. The collected cells were
counted and 1×106 cells/aliquots were assayed in tripli-
cates. Cells were lysed with a 2% SDS solution buffered with
20 mM Tris-HCl (pH 7.5) containing 1 mM PMSF pro-
teinase inhibitor. Lysed samples were frozen in liquid nitro-
gen overnight. Thawed samples were subjected to vigorous
vortexing for about 10 s followed by warming for 10 min
at 65◦C. Next, 0.5 ml of 200 mM KCl in 20 mM Tris-HCl,
pH 7.5, was added, and the mixture was passed through a 1
ml pipette tip 5 times. SDS-KCl precipitate formation was
induced by cooling the samples on ice for 5 min, and the
precipitate was then collected by centrifugation at 3000 ×g
for 5 min at 4◦C, and the supernatant was saved to measure
free DNA. The DPC-containing pellet was resuspended in
1 ml 100 mM KCl, 20 mM Tris-HCl, pH 7.5, heated for 10
min at 65◦C followed by chilling on ice and centrifugation
for 5 min at 3000xg. The washing step was repeated twice,
and the 1 ml supernatant of the first centrifugation and the
2 ml of washing fractions were combined resulting in the
free DNA fraction. The final SDS-KCl precipitate was re-
suspended in 1 ml 100 mM KCl, 10 mM EDTA, 20 mM
Tris-HCl, pH 7.5 before Prot K was added to a final con-
centration of 0.2 mg/ml followed by incubation for 3 h at
50◦C. SDS was precipitated by chilling samples on ice, and
after addition of 10 l BSA (50 mg/ml) the SDS precipitate
was centrifuged, and the supernatant was used to determine
the amount of DPC-containing DNA by electrophoresis on
0.7% agarose gel stained with ethidium-bromide for visual-
ization. The gel was scanned and quantitated using a Ty-
phoon Trio Imager (GEHealthcare). The amount of DNA-
protein crosslinking was determined as the percentage of
SDS/KCl-precipitable DNA in the total DNA (SDS/KCl
precipitated plus soluble free DNA).
BrdU comet assay with Prot K treatment
The bromodeoxyuridin (BrdU) comet assay modified with
Prot K treatment is a DPC-specific version of our formerly
published method (41) with modifications based on a pre-
viously used comet method which was improved to specifi-
cally measure FA-induced DPCs (42,43). Our specific mod-
ifications are detailed below. The comet assay is a sensitive
single-cell electrophoresis assay that can be used to detect
variousDNA lesions. The alkaline version of the assaymea-
sures single- and double-strand DNA breaks and alkali la-
bile sites, while double-strand breaks can be detected by the
neutral version of the assay (44,45). Pulse labelling the cells
with BrdU, a thymidine analoguemainly used to distinguish
newly synthesized DNA, renders this assay highly S phase
specific (41).
Under standard alkaline conditions, crosslinks can be de-
tected via the decrease in DNA migration, but DNA-DNA
intra- or inter-strand crosslinks andDPCs cannot be distin-
guished. Since our aim was to detect DPCs in the S phase,
we modified the standard BrdU alkaline protocol in a way
that the assay became highly specific for detecting repair
processes during DNA replication and DPCs.
Exponentially growing cells were plated in DMEM
supplemented with 10% fetal bovine serum (FBS)
(Sigma), 100 g/ml streptomycin sulphate and 100
U/ml penicillin and grown for 24 h. Cells were transfected
with Lipofectamine using different plasmid constructs
(silencing-resistant N-terminally FLAG-tagged constructs:
SPARTAN(4A) pIL 2854, SPARTAN(HEAA) pIL 2337,
SPARTAN(PIP) pIL2338, SPARTAN(UBZ) pIL2336 and
SPARTAN(PIP/UBZ) pIL2339 as specified in (21,48).
The following day, cells were collected, replated in du-
plicate to be left untreated or for FA treatment. At 48
h post-transfection, the growth medium was changed to
fresh DMEM containing 20 M BrdU at 37◦C for 20
min, and the cells were washed twice with PBS. After 2 h
of FA treatment (250 M, 500 M, 750 M), cells were
washed, left for 3 h recovery where indicated, or harvested
immediately and resuspended in ice-cold PBS. Cells were
pelleted by centrifugation, resuspended in 150 M ice-cold
H2O2 diluted in PBS, and kept on ice for 5 min. The
H2O2 treatment was employed to induce strand breaks,
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as an alternative to gamma irradiation which is also used
to detect cisplatin, mitomycin C and FA-induced DNA
interstrand crosslinks (42,46). For the rescue experiment
illustrated in Figure 3A, the BrdU comet analysis was
performed after 500 M FA treatment for 2 h and 3 h
of recovery and the release of non-crosslinked DNA was
achieved using 100 M ice-cold H2O2 diluted in PBS.
H2O2 was removed by washing twice with ice-cold PBS
and, after the last centrifugation, cells were resuspended in
0.75% low melting agarose diluted in PBS kept at 37◦C.
The lysis solution (2.5MNaCl, 0.1MEDTA, 10mMTris
[pH 10], 1% Triton X-100 and 0.5% sarcosyl) was supple-
mented with Prot K (Sigma-Aldrich) to a final concentra-
tion of 0.8% w/v. Samples were kept in Prot K-containing
lysis solution at 4◦C overnight. The lysis was performed
overnight at 4◦C in Prot K-containing lysis solution to elim-
inate possible artificial break induction at AP sites, which
can be generated during Prot K treatment at the regularly
used temperature of 37◦C (47).
Alkaline electrophoresis, immunostaining and imaging
were performed as published previously. For immunostain-
ing, rat anti-BrdU primary antibody (BioRad, OBT0030G,
1:300) and goat anti-rat AlexaFluor488 conjugated sec-
ondary antibody (Molecular Probes Inc. A11006, 1:400)
were applied. Imaging was performed using Zeiss Axio-
scope fluorescent microscopy, and quantitation of images
was done with the Komet 5.0 software (Kinetic Imaging
Ltd., Liverpool, UK).
DNA fibre assay
Exponentially growing HEK 293 cells were pulse labelled
with 20 M iododeoxyuridine (IdU) at 37◦C for 20/30
min, washed twice with prewarmed PBS and labelled with
200 M BrdU for 40/60 min (for untreated control) or ex-
posed to 500 MFA supplemented with 200 MBrdU for
40/60 min. In the experiment illustrated in Figure 4E, cells
were plated at 80–90% confluency in 6-well plates and were
transiently transfected with Turbofect (Thermo Scientific)
transfection reagent for 5 h using 4 g of human expression
vector pRK2F expressing FLAG-Spartan(WT) (pIL2335),
HEAA-mutant FLAG-Spartan (pIL2337) in siRNA resis-
tant form or empty vector (pIL 1440), as published earlier
(21,48). Fiber assay was performed 48 h after transfection.
Isolation of DNA fibres and immunolabelling were car-
ried out as described previously (49). Briefly, 2 l of cells
resuspended in PBS (106 cells/ml) were diluted 1:2 with
unlabelled cells and spotted onto clean glass slides. Cells
were lysed with lysis solution (0.5% sodium dodecyl sul-
phate (SDS) in 200 mMTris-HCl (pH 5.5), 50 mMEDTA).
Slides were tilted at 15◦ to the horizontal, allowing a stream
of DNA to run slowly down the slide. Next, slides were
air-dried and fixed in methanol-acetic acid (3:1). Fixed fi-
bres were rehydrated in water and denatured (2.5 M HCl
for 1 h). BrdU incorporation was detected using rat anti-
BrdU antibody (1:300; BioRad, OBT0030G), and IdU in-
corporation was followed using mouse anti-IdU antibody
(BD Biosciences, 347580, 1:400). Slides were washed and
incubated with fluorescently labelled secondary antibod-
ies (Alexa Fluor488-conjugated goat anti-rat IgG antibody
(Molecular Probes Inc. A11006, 1:400,) and Cy3-labeled
sheep anti-mouse IgG antibody (Sigma Aldrich, C2181,
1:400) to detect BrdU and IdU, respectively. After extensive
washing with PBS, slides were stained in mounting medium
containing glycerol and DAPI. DNA fibres were imaged us-
ing an Olympus confocal laser scanning microscope. The
lengths of DNA tracks corresponding to IdU and BrdU la-
belling were measured using the Olympus Fluoroview 2.0
software. In each experiment, minimum 100 independent fi-
bres were analysed. Results are illustrated as±SEMof three
independent experiments.
Cell viability assay
Exponentially growing HEK 293 cells were plated at 70%
confluency in 6-well plates. After 24 h, cell transfections
were carried out according to the instructions of the manu-
facturer, using the Lipofectamine 2000 (Invitrogen) trans-
fection reagent. Cell competition-based cell viability as-
say was performed as described earlier (21). The cells
were transfected with the following siRNA-resistant N-
terminally FLAG-tagged plasmids: pIL2335 containing
WT SPARTAN, pIL2615 containing RAD18 and pIL1440
containing FLAG-empty vector. After 24 h, the cells were
treated with FA (Sigma) for 2 h and washed briefly three
times with PBS. After 7 days of culturing, the ratio of GFP-
positive and GFP-negative cells was determined by flow cy-
tometry (FACSCalibur, BDBiosciences). The percentage of
viability was calculated by defining the viability of untreated
HEK 293 cells stably expressing control shRNA as 100%.
Resazurin fluorometric cell viability assay
Exponentially growing HEK 293 cells were plated at 60%
confluency in 6-well plates. After 24 h, cell transient trans-
fections were carried out according to the instructions of
the manufacturer, using the Lipofectamine 2000 (Invitro-
gen) transfection reagent. The cells were transfected with
the following siRNA-resistant N-terminally FLAG-tagged
plasmids: pIL2335 containing WT SPARTAN, pIL2854
containing SPARTAN(4A), pIL2331 containing SPAR-
TAN(HEAA) and pIL1440 containing FLAG-empty vec-
tor. One day after transfection, siRNA-transfected cells
were treated for 2 h with different concentrations of FA
(0 M, 250 M, 500 M, 1000 M, 2000 M) in serum-
free DMEM. After 2 h treatment, cells were washed three
times with prewarmed PBS, harvested and seeded in trip-
licate in 96-well plates at a density of 10 000 cells/well in
a volume of 100 ml of DMEM containing fetal calf serum
and penicillin/ streptomycin. After 2 days of culturing, 0.15
mg/ml of resazurin (Sigma, R7017-1G) solution in PBSwas
mixed with DMEM (100 ml) in a ratio of 20: 100 and was
added to each well. After 5 h of incubation at 37◦C, cell
viability was monitored by measuring fluorescence with ex-
citation wavelength at 565 nm and emission wavelength at
580 nm in a Fluoroskan Ascent FL (Thermo Scientific) flu-
orimeter. The fluorescent signal generated from the assay
is directly proportional to the number of living cells in the
sample. Percentages of living cells were calculated according
to the calibration curves of the appropriate cell lines (50).
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Cell cycle analysis by flow cytometry
Cell cycle analysis was carried out using flow cytometry.
Cells were plated in 100 mm plates in complete medium.
After 24 h, treatment with 500 M FA was applied for 2 h,
and the cells were washed three times with PBS. Cells were
trypsinized, harvested and fixedwith 70% ethanol overnight
at -20◦C. The following day, ethanol was removed by wash-
ing with 1xPBS, and the cells were resuspended in phos-
phate buffer containing 10 g/ml RNaseA and 20 g/ml
propidium iodide (Sigma) and incubated at room temper-
ature for 30 min. For flow cytometry measurements, the
BD FACSCalibur (BD Biosciences) flow cytometer and for
quantitative analysis CellQuestTM (BD Biosciences) was
used.
RESULTS
Spartan has a DNA-dependent protease activity
Spartan has four well-defined distinct motifs includ-
ing an N-terminal metalloprotease-like domain (SprT), a
DNA-binding domain labelled as KKGK (48), a PCNA-
interacting (PIP) and a C-terminal ubiquitin-interacting
(UBZ) domains (Figure 1A). Our previous study (21) us-
ing various point-mutant SPARTAN constructs in the com-
plementation study of Spartan-silenced cells revealed the
importance of the SprT motif in providing UV-resistance;
however, no particular function has been assigned to this
domain.
During our effort to purify Spartan-interacting proteins
from human cells stably expressing tandem-affinity tagged
Spartan or various other proteins, we realized that the full-
length Spartan becomes quite rapidly degraded in the cell
extract, resulting in at least two distinct bands the molec-
ular sizes of which indicate that the cleavage might occur
after the N-terminal SprT domain (Figure 1B), but due to
the unusual electrophoretic mobility of TAP-Spartan this
conclusion is not definite.Moreover, whenwe overexpressed
human Spartan in yeast cells for purification purposes, we
also noticed its instability (Figure 1C, lanes 1–4). Impor-
tantly, adding DNase to the cell breaking buffer inhibited
the cleavage of Spartan very significantly (Figure 1C, lanes
5–8). Moreover, when we purified the Spartan(4A) mutant,
in which the DNA-binding KKGK amino-acids were mu-
tated to AAAA, we realized that the stability of this mutant
is much higher than that of the wild-type protein (Figure
1C, lanes 9–12). Finally, under cold conditions and in the
presence of DNAse we managed to obtain Spartan wild-
type and Spartan(4A) proteins with high degree of purity
(Figure 1D). These experiments suggested that the cleav-
age of Spartan is DNA-dependent. As further support, we
found that wild-type purified GST-FLAG-Spartan as well
as FLAG-Spartan are stable when incubated in the absence
ofDNA (Figure 1E, lanes 1 and 3); however, whenwe added
long single-stranded DNA (ssDNA) to the reaction all of
the Spartan protein present became degraded (Figure 1E,
lanes 2 and 4). Importantly, we noticed that in the paral-
lel reaction using purified Spartan(4A), the degradation of
this DNA-binding mutant was significantly impaired (Fig-
ure 1E, lanes 5 and 6). We kinetically compared the wild-
type and the mutant protein for their self-degrading activ-
ity in the presence of DNA (Figure 1F, compare lanes 2–6
to 7–11) and noticed that the wild-type protein is several-
fold more prone to degradation. We concluded that Spar-
tan exhibits an intrinsic DNA-dependent protease activity
and is able to cleave itself. Next, we asked whether the cleav-
age activity of Spartan is limited to itself or it can degrade
other proteins as well. To this end, we assayed the protease
Spartan on various highly purified potential protein sub-
strates in the absence or presence of DNA (Figure 1G). Re-
markably, Spartan was able to cleave in a DNA-dependent
manner not only itself but also the DNA-binding proteins
Fan1, HLTF and yRad5 while many proteins such as BSA,
PCNA and RFC were inaccessible to its protease activ-
ity. We note that certain proteins that have high affinity to
DNA, such as RFC and RPA, exhibited inhibitory activ-
ity against the protease Spartan, which also depended on
their concentration (Figure 1G and data not shown) sug-
gesting that the efficiency of competing with other proteins
for DNA binding could be a rate-limiting step in the ac-
tion of the protease Spartan. This could be particularly im-
portant at the stalled replication fork where the exposed ss-
DNA tracks rapidly become covered by RPA. To systemat-
ically check DNA structural requirements, we tested vari-
ous DNAs for stimulation (Figure 1H). We found that var-
ious DNA structures could stimulate the protease activity
at some level, but X174 ssDNA stimulated the most, and
the ss75-mer oligonucleotide was also quite effective, while
double-stranded or nicked plasmid DNA or the 75/45-
mer partial heteroduplex stimulated quite weakly. Taken to-
gether, our observations are consistent with a model depict-
ing that Spartan is targeted to exposed ssDNA such as that
found in case of fork stalling, where its protease activity can
remove some DNA-bound proteins.
Spartan is required for DPC removal
To reveal whether Spartan is involved in DPC removal in
vivo, we monitored the DPC content of genomic DNA by
separating the total genomic DNA into two fractions, a
free-DNA- and a DPC-containing one, using a previously
established SDS-KCl protein precipitation technique. We
induced DPCs in control and Spartan-silenced cell lines by
FA treatment and followed DPC appearance after 2 h of
treatment and subsequently DPC removal at 3 h as well as
6 h after washing out FA from the medium of the cells. As
shown in Figure 2A, FA-treatment highly increased DPC
formation (∼20-fold), and the repair by direct-removal of
DPC from the genomic DNA in the recovery period was
apparent. Importantly, we found that Spartan-silenced cells
exhibited a somewhat higher amount of DPC even at the
end of the 2 h FA-treatment and retained higher amounts
of DPC than theWT control cells during the 3 h and 6 h re-
covery time following FA treatment (Figure 2A). From this
experiment, we conclude that in vivo Spartan has a role in
the removal of DPCs.
Spartan has been suggested to act when replication stalls
at a DNA lesion. To reveal whether Spartan deficiency
causes impairment in the replication of DPC-containing
DNA, first we used the BrdU comet assay (41) combined
with a Proteinase K (Prot K) treatment. Including Prot K
treatment was necessary since no specific agent is known
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Figure 1. Spartan exhibits DNA-dependent protease activity. (A) Schematic representation of the domain structure of human Spartan. Spartan con-
tains an SprT-like metalloprotease, an SHP, a PCNA-binding (PIP) and a ubiquitin-binding (UBZ) domain. Asterisks and the displayed amino acids
indicate the sites mutated to generate the protease-deficient Spartan mutant Spartan(HEAA) (HE to AA), the DNA-binding Spartan(4A) (KKGK to
AAAA), the PCNA-binding Spartan(PIP) (YF to AA), the UBZ-binding Spartan(UBZ) (C to S) and the PCNA-binding and UBZ-binding double mu-
tant Spartan(PIP/UBZ) (YF/C to AA/S). (B) Spartan is cleaved rapidly in human cell extract. Total cell lysates (lanes 1 and 4) generated from human
cells stably expressing tandem affinity-tagged Spartan or control Mgs1 were used for the purification on two subsequent affinity beads for 16 h (lanes 2
and 5) and an additional 4 h (lanes 3 and 6). The positions of the FLAG-tagged proteins were visualized by Western blot using anti-FLAG antibody. (C)
Stability of human Spartan overexpressed in yeast. GST-FLAG-tagged wild-type Spartan (lanes 1–8) and DNA-binding mutant Spartan(4A) (lanes 9–12)
were expressed in yeast, and the generated cell lysates were incubated for the indicated lengths of time at room temperature. In lanes 5–8, DNaseI was
added during cell lysis. The stability of Spartan was followed by Western blot using anti-FLAG antibody. (D) Purity of purified Spartan, sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of purified GST-FLAG-Spartan(WT) and GST-FLAG-Spartan(4A) stained with Coomassie
blue (E) DNA-dependent self-cleavage of Spartan. Spartan and Spartan(4A) were purified as GST-FLAG- (lanes 1–2) or FLAG-fusion (lanes 3–6) pro-
teins. Purified proteins were incubated in the absence or presence of X174 single-stranded DNA (ssDNA) for 2 h at 37◦C followed by SDS-PAGE and
Coomassie blue staining. The asterisk indicates the position of a co-purifying contaminating protein which can serve as a loading control. (F) Comparison
of the self-cleavage activity of the wild-type and theDNA-bindingmutant Spartan proteins. Purified Spartan (lanes 2–6) and Spartan(4A) (lanes 7–11) were
incubated for various lengths of time in the presence ofX174 ssDNA. (G) Spartan can cleave certain DNA-binding proteins in a strictly DNA-dependent
manner. Purified BSA, Fan1, ubiquitin-PCNA, PCNA, RFC, HLTF and yRad5 were incubated without (control) or with Spartan for 2 h at 37◦C in the
absence or presence of X174 ssDNA as indicated. Lane 4 of the lower two panels shows the no reaction control, in which all the reaction components
were mixed and then boiled immediately. (H) Comparison of the activating potential of various DNA structures on Spartan protease. Purified Spartan was
mixed with purified Fan1 and incubated either alone or with various types of DNA (X174 ssDNA, nicked plasmid dsDNA, plasmid dsDNA, 75-mer
oligonucleotide, 75/45-mer partial heteroduplex oligonucleotides, each at 100 ng/l) for 2 h at 37◦C. The percentage of cleavage activity was quantitated
compared to the amount of Spartan and Fan1 in the sample containing no DNA.
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Figure 2. Spartan facilitates protein–DNA crosslink (DPC) repair. (A) Monitoring of in vivoDPC removal. Exponentially growing cells were treated with
500 M FA for 2 h, washed and left to recover until 3 and 6 h. After an SDS/KCl precipitation assay, the quantification of the DPC-containing and the
free DNA-containing fractions was carried out, and the percentage of DPCs in total DNA (DPC+free DNA) was graphed. Error bars indicate ± standard
error of the mean of three independent experiments. (B) Schematic illustration of the experimental set-up of the Prot K-modified alkaline BrdU comet
assay. Asynchronously growing HEK 293 cells were pulse labelled with BrdU for 20 min and treated with FA for 2 h. Cells were harvested, and DNA
strand breaks were induced with H2O2 exposure to release DNA. For the detection of the amount of proteins crosslinked to DNA, the lysis solution was
supplemented with Prot K (Prot K+) or lysed without Prot K (Prot K-) before electrophoresis and immunostaining using BrdU-recognizing antibody. (C)
Effect of FA exposure on post-replication repair using the Prot K-modified BrdU comet assay. Representative images of control HEK 293 cells illustrate the
dose-dependence of FA exposure and the difference caused by Prot K treatment. (D) Quantitation of the experiment shown in (C). Error bars indicate ±
standard error of the mean of three independent experiments. Statistical analysis was made by Student’s t-test. Statistical significance was labelled by ***: P
< 0.001. (E) Dose dependence of FA exposure on HEK 293 cells stably expressing SPARTAN shRNA. Representative images illustrate the effect of FA and
Prot K treatments. (F) Quantitation of the experiment shown in (E). Error bars indicate ± standard error of the mean of three independent experiments.
Statistical analysis was made by Student’s t-test. Statistical significance was labelled by **: P < 0.01, ***: P < 0.001. (G) Quantitative comparison of
FA-induced post-replicative repair delay in cells stably expressing control or SPARTAN shRNA. The percentage of DPC-caused DNA maturation delay
was calculated as a difference between Prot K+ and Prot K- samples ( comet tail DNA (%)). The data were obtained fromminimum 300 cells measured in
three independent experiments. Statistical analysis was made by Student’s t-test. Statistical significance was labelled by ***: P< 0.001, NS: not significant.
Corresponding data are shown in Figure 2D and F. (H) The PCNA-binding and the Ubiquitin-binding domains of Spartan are required for DPC-repair.
HEK 293 cells stably expressing control shRNA were transfected with FLAG-empty vector expressing FLAG and cells stably expressing SPARTAN
shRNA were transfected with FLAG-empty vector expressing FLAG, and siRNA-resistant FLAG-tagged SPARTAN(PIP) mutant, SPARTAN(UBZ)
mutant, SPARTAN(PIP/UBZ) or SPARTAN(WT). Cells were treated for 2 h with 500 M FA and analysed after 0 and 3 h of recovery by comet assay
Statistical analysis was made by Student’s t-test. Statistical significance was labelled by ***: P < 0.001, NS: not significant.
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that causes only DPCs without any other types of damage
such as DNA–DNA crosslinks or single-stranded breaks,
and we wanted to make our assay highly specific for moni-
toring only DPC-caused events. For comet assay, which is a
single-cell electrophoresis assay, we pulse labelled the cells
with the thymidine analogue BrdU to distinguish replicat-
ing cells. During electrophoresis, migration of crosslinked
DNA is reduced, and determination of DPCs is accom-
plished by the measurement of the reduction in induced
DNAmigration. To distinguish between crosslinked and in-
tact DNA that is not damaged by FA, DNA migration can
be induced by H2O2 following the FA treatment, and the
reduction in induced DNA migration relative to the FA-
untreated but H2O2-treated control can be detected as a
measure of crosslinking.
The outlines of the DPC-specific comet assay method we
employed are shown in Figure 2B. First, cells were pulse la-
belled with BrdU to visualize replicating cells only, and FA
treatment was applied to induce DPCs (Figure 2B). Since
during electrophoresis the migration of DPC-containing
DNA is highly reduced, keeping the whole DNA molecule
in the comet head, we applied a DNA fragmenting H2O2
treatment, which enabled the resulting DNA fragments to
migrate to the tail of the comet. After H2O2 treatment,
cells were embedded in agarose and immediately lysed, thus,
no further repair process was allowed to remove H2O2-
induced strand breaks before single-cell electrophoresis. To
further sensitize the comet assay for DPCs and distin-
guish between FA-induced DNA–DNA and protein–DNA
crosslinks, in a parallel sample, we added Prot K to the ly-
sis buffer to remove crosslinked protein residues from the
DNA. Due to the removal of DPCs, the protein-free high
molecular weight DNA––which is not able to migrate in
agarose––behaves as a single-stranded break having free
ends at the stalled replication fork. Under denaturing alka-
line conditions, it is able to relax, unwind, and unhook in the
vicinity of free ends, and the forming free DNA loops mi-
grate into the tail, resulting in a higher percentage of comet
tail DNA. After the removal of the protein part of the DPC,
the shorter, newly replicated still non-ligated DNA frag-
ments like the Okazaki fragments are also capable of mi-
grating into the tail, forming higher amounts of tail DNA.
Using the setup detailed above, the difference between
the comet tail DNA percentage of Prot K-treated (Prot
K+) and untreated (Prot K-) samples reflects the amount of
DPCs left unrepaired. To test the sensitivity of the method,
we treated cells with increasing concentrations of FA and
monitored the changes in comet tail DNA percentage with
and also without Prot K treatment (Figure 2C). We found
that FA treatment causes a concentration-dependent de-
crease in DNA migration, and, as expected, the difference
in the percentage of tail DNA of Prot K+ and Prot K- sam-
ples gradually increases, reflecting the presence of increas-
ing amounts of DPCs correlating well with the applied dose
of FA (Figure 2D). Thus, the Prot K-modified BrdU comet
assay we employed is suitable for the precise detection of
DPC removal in replicating cells.
Next, we used this technique to investigate whether Spar-
tan has a role in DPC removal in replicating cells using
Spartan-silenced HEK 293 cell lines generated by the stable
expression of Spartan-specific shRNA in the DPC-specific
BrdU comet assay (Figure 2E and Supplementary Figure
S1A). As a result of increasing doses of FA, higher amounts
ofDNA remained in the comet head in the Spartan-silenced
cell line than in the control cell line (Supplementary Fig-
ure S1B). However, the difference between the Spartan-
knockdown and the control cell line can be observed more
prominently after Prot K treatment (Figure 2E and F). We
calculated the difference between the comet tails of Prot K-
treated and untreated samples ( comet tail DNA (%)) for
all FA concentrations we used (250–750M) and compared
these data points between the control and the Spartan-
silenced cell lines. This analysis revealed a high degree of de-
ficiency in DPC-removal in Spartan-silenced cells at all ex-
amined FA concentrations (Figure 2G). We also monitored
repair after 0 and 3 h of recovery following FA treatment
and compared the effect of expression of shRNA-resistant
PIP and UBZ mutant Spartan proteins in Spartan-silenced
cells on DPC removal in replicating cells (Figure 2H, Sup-
plementary Figure S1C and D). We found that wild-type
Spartan was able to complement the deficiency of Spartan
knockdown cells, but the PIP and UBZ mutant Spartans
were unable to restore the deficiency of DPC-repair even
after 3 h of recovery. Taken together, SPARTAN is required
for DPC-repair in replicating cells, in which its PCNA- and
ubiquitin-binding domains play an essential role.
The DNA-binding and the protease domains of Spartan con-
tribute to cell resistance against DPCs
To test our hypothesis that the protease activity of Spar-
tan is indeed required for DPC removal and to further con-
firm that the observed phenotype is Spartan-dependent,
we employed a complementation assay (Figure 3A). First,
to rescue the effect of Spartan silencing on FA-induced
DPC accumulation, we ectopically expressed silencing-
resistant FLAG-Spartan in two independently generated
stably Spartan-depleted cell lines (#7 and #12) and carried
out the DPC-specific comet assay applying 2 h of FA treat-
ment and 3 h of recovery (Supplementary Figure S2A and
B). We found that ectopic expression of silencing-resistant
FLAG-Spartan resulted in the restoration of DPC-repair,
indicating that the impairment in the silenced cell lines was
indeed caused by the absence of Spartan (Figure 3A). Inter-
estingly, we noticed that the ectopic expression of Spartan
conferred some additional protection against crosslink ac-
cumulation as compared to the control cell line (indicated
by the  comet tail DNA (%) value in Figure 3A and Sup-
plementary Figure S2A), which can be explained by the de-
pendence of DPC repair on the cellular concentration of
Spartan.
Next, we tested the effect of the inactivation of the pro-
tease andDNA-binding activities of Spartan by a cell viabil-
ity assay employing FA treatment. We ectopically expressed
the siRNA-resistant forms of wild-type, DNA-binding mu-
tant Spartan(4A), and SprT-mutant Spartan(HEAA) in
Spartan-silenced cells and compared their FA sensitivity
(Figure 3B). We found that while wild-type Spartan com-
pensated the negative effect of Spartan depletion on cell sur-
vival quite well, neither Spartan(4A) nor Spartan(HEAA)
was able to significantly rescue the deleterious effect of
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Figure 3. TheDNA-binding and the protease domains of Spartan contribute to cell resistance againstDPC. (A) Complementation of Spartan-silenced cells.
Ectopic expression of silencing-resistant Spartan complemented the DPC-repair deficiency of Spartan-silenced cells as revealed by the Prot K-modified
BrdU comet assay. Cells were treated with 500 M FA for 2 h, harvested after 3 h recovery followed by 100 M H2O2 treatment. Two independent
SPARTAN stable knockdown cell lines (Spartan #7 and #12) were assayed, and ± standard error of the mean was calculated from three independent
experiments. Statistical analysis was made by Student’s t-test. Statistical significance was labelled by *P< 0.05, **P< 0.01, ***P< 0.001. (B) Cell viability
assay of HEK 293 cells depleted of endogenous Spartan expressing siRNA-resistant FLAG-tagged Spartan or Spartan(4A) mutant or Spartan(HEAA)
mutant proteins. Resazurin Fluorometric Cell Viability Assay was performed after 2 days of mock or FA treatment. Percentage of viability was calculated
by defining the viability of untreated HEK 293 cells stably expressing the corresponding shRNA as 100%. Error bars indicate± standard error of the mean
from three independent experiments. The expression of the siRNA-resistant wild-type and mutant Spartan proteins are verified with -FLAG antibody in
Western blot analysis. (C) The DNA-binding and the SprT domains of Spartan are required for DPC-removal. Representative images of FA-treated cells
analysed by the DPC-specific BrdU comet assay. HEK 293 cells stably expressing control shRNA were transfected with FLAG-empty vector expressing
FLAG and cells stably expressing SPARTAN shRNAwere transfected with FLAG-empty vector, siRNA-resistant FLAG-tagged SPARTAN(4A)mutant,
siRNA-resistant SPARTAN(HEAA)mutant or siRNA-resistant SPARTAN(WT). (D) Quantitation of post-replication repair of DPC-containing DNA
in cells expressing DNA-binding- and SprT-mutant Spartan proteins. Three independent experiments as shown in Figure 3C were quantitated, and ±
standard error of the mean was calculated. Statistical analysis was made by Student’s t-test. Statistical significance was labelled by *: P < 0.05, **: P <
0.01, ***: P < 0.001.
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Figure 4. SPARTAN knockdown leads to deficiency during replication of FA-inducedDNAdamage. (A) Schematic illustration of the strategy of replication
fork analysis via the DNA fibre assay. Exponentially growing HEK 293 cells were pulse labelled with 20 M IdU (red label) at 37◦C for 20 min then mock
treated or exposed to 500 M FA supplemented with 200 M BrdU (green label) for 40 min. DNA fibres were imaged using a confocal laser scanning
microscope. The lengths of DNA tracts were measured using Olympus Fluoroview FV1000 2.0 software. Minimum 100 fibres/experiment were measured,
and at least three independent experiments were carried out. (B) Representative images of fibres taken from an undisturbed and an FA-treated sample of
HEK 293 cells stably expressing control or SPARTAN shRNA as indicated. (C) Replication fork movement on FA-damaged DNA is inhibited in Spartan-
depleted cells. DNA fibre experiment was carried out as detailed in (A). Data from the measurement of second track lengths are illustrated by distribution
curves. Statistical analysis was made by Student’s t-test p(1-2)< 0.001, p(1-3) < 0.001, p(2-4) < 0.001. (D) Schematic illustration of the strategy of replication
fork analysis via the DNA fibre assay to detect the effect of the ectopic expression of the Spartan(HEAA) mutant. (E) Inhibited replication fork movement
on FA-damaged DNA in Spartan-depleted cells was not rescued by Spartan(HEAA). Exponentially growing HEK 293 cells were pulse labelled with 20
M IdU (red label) at 37◦C for 30 min then mock treated or exposed to 500 M FA supplemented with 200 M BrdU (green label) for 60 min. Data
from the measurement of second track lengths are illustrated by distribution curves. Statistical analysis was made by Student’s t-test p(1-2) < 0.001, p(2-4)
< 0.001, p(3-4) < 0.001, p(4-6) > 0.05 (non-significant), p(3-5) < 0.05, p(5-6) < 0.001, p(6-8) < 0.001, p(4-8) < 0.001. (F) Spartan silencing affects cell cycle
progression and leads to a G2/M accumulation after FA exposure. Cell cycle analysis was carried out employing the propidium iodide staining method
to measure the DNA content by flow cytometry after 2 h of FA treatment followed by 0–24 h recovery. Cells were harvested at the indicated time points,
fixed with ice-cold 70% ethanol overnight, and DNA was stained with propidium-iodide.
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Spartan silencing, though their ectopic expression levels
were similar (Figure 3B, right panel).
We also used the BrdU comet assay in complementation
study. FA-induced crosslinks highly reduced tail DNA for-
mation (Figure 3C upper row), and as a result of Prot K
treatment free DNA could migrate into the comet tail (Fig-
ure 3C lower row). Compared to the control cells trans-
fected with an empty vector, ectopic expression of siRNA-
resistant Spartan decreased Prot K-induced tail formation
significantly (see Figure 3C shSPARTAN+Spartan(WT),
lower row last panel), as revealed by the lower amount
of tail DNA and bigger head of comets, reflecting much
lower amounts of unrepaired, FA-induced DPCs. In con-
trast, expression of siRNA-resistant Spartan(4A) and Spar-
tan(HEAA) could not reduce tail DNA formation, and the
phenotype observed was similar to that of the empty vector-
transfected Spartan-silenced sample. Quantitative compar-
ison of the difference in the tail DNA percentage of Prot
K-treated and untreated samples revealed that in contrast
to wild-type Spartan, expression of Spartan(4A) and Spar-
tan(HEAA) was not able to rescue the DPC-repair defi-
ciency caused by Spartan knockdown (Figure 3D). From
these results, we conclude that the DNA-binding- and
protease-domain mediated activities of Spartan are impor-
tant determinants of the function Spartan has in the pro-
tection against the genotoxic effects of FA-induced DPCs.
Spartan facilitates immediate bypass of FA-induced DNA
damage
One of the main hallmarks of replication stress is the ab-
normal slowing of replication fork movement, which can
eventually lead to the stalling of the replication fork. Hav-
ing established the requirement for Spartan in DPC-repair
in replicating cells, our next question was whether Spartan
has a role in the immediate bypass of DPCs, which can pose
strong barriers to the movement of not only the replica-
tive polymerases but the translesion synthesis polymerases
as well. To monitor the speed of replication, we used the
DNA fibre assay with which we can follow the elongation
of the nucleotide analogue-labelled nascent DNA track at
the single molecule level. As shown in Figure 4A, replicat-
ing DNA was visualized by first pulse labelling the cells
with iododeoxyuridine (IdU, red label) followed bymock or
FA treatment, performed simultaneously with BrdU pulse
labelling before immunodetection of the nucleotide ana-
logues via microscopy of the individual, newly replicated
DNA tracks. We found that FA treatment significantly de-
creased replication fork speed as revealed by the shorter sec-
ond tracks (green label) shown in the representative images
of our DNA fibre experiments (Figure 4B). To unravel if
Spartan can facilitate the bypass of FA-inducedDNA dam-
age, we compared Spartan-depleted and control cells and
noticed that the lengths of the second tracks of Spartan-
silenced cells are significantly shorter compared to those of
control cells after FA treatment, reflecting a significantly
stronger inhibitory effect of FA-induced damage on imme-
diate bypass in the absence of Spartan (Figure 4B).Measur-
ing the length distribution of the second DNA tracks of in-
dividual replication forks (Figure 4C) revealed that Spartan
knockdown led to somewhat slower replication fork move-
ment under unchallenged conditions, which might reflect
the presence of some endogenous damage in the absence
of exogenous FA treatment. However, more significantly re-
duced fork progression could be detected after FA treat-
ment, and in Spartan-silenced cells more than a two-fold
shortening of the average second track length was detected.
We also tested whether the predicted protease domain
(SprT) of Spartan is required during replication of DPC-
containing DNA (Figure 4D and E, and Supplementary
Figure S2E) using 30 min IdU labelling followed by 60 min
of FA treatment with a simultaneous BrdU labelling. We
found that in contrast to the wild-type Spartan, expression
of the Spartan(HEAA) protein was not able to rescue the
Spartan knockdown cells from the replication inhibitory
effect of FA treatment (Figure 4E) indicating the require-
ment for the Spartan protease-like domain. These findings
are consistent with a model in which Spartan degrades
the protein component of the replication fork-movement-
blocking DPC, leaving only a short peptide bound to the
DNA thus rendering the DNA accessible to immediate by-
pass by translesion synthesis polymerases. FA exposure-
induced DNA damage results in G2/M accumulation of
the cell cycle progression in cells with certain DNA re-
pair deficiencies (51,52). Moreover, knockout of the poten-
tial Spartan homologue yeastWSS1 results in a strong G2
cell cycle arrest after FA exposure (32). Thus, impairment
in DPC repair and replication of DPC-containing DNA
caused by Spartan deficiency can also be expected to disturb
normal cell cycle. To explore this hypothesis and to deter-
mine whether FA exposure leads to altered cell cycle pro-
gression, we compared control and Spartan-depleted cells
by flow cytometry analysis using propidium iodide stain-
ing (Figure 4F). We detected some G2/M accumulation in
Spartan-depleted cells compared to control cells even with-
out any treatment. However, after FA treatment a more
marked difference was observed. At 3 h post-treatment, a
late S/G2 accumulation was found and, remarkably, cells
with more than 2CDNA content also appeared in Spartan-
depleted cells. These binucleated cells possibly reflect cells
with micronuclei and aberrant unresolvable mitotic struc-
tures such as chromatin bridges, which we also noticed dur-
ing the microscopic analysis of the BrdU comet assay (Sup-
plementary Figure S2D). Moreover, after 24 h of FA expo-
sure, control cells showed an increased S-phase blockage,
which inhibits exit from the S phase with damaged DNA;
in contrast, Spartan-silenced cells displayed a noticeable
accumulation of G2/M-phase cells. These changes reflect
that Spartan-depleted FA-treated cells leave the S phase
faster than control cells, possibly with unrepaired DPCs
and abnormal replication intermediates, which might ex-
plain Spartan deficiency-caused genomic instability.
Spartan and Rad18 act together in protecting the genome
from DPCs
No particularly defined pathway has been assigned to DPC
repair yet, and the discovery of the requirement for the pro-
tease Spartan in the replication of DPC-containing DNA
raised the question whether it constitutes an independent
DPC repair pathway or acts together with other fork res-
cue pathways. In a wide variety of species, Rad6-Rad18-
12 Nucleic Acids Research, 2016
dependent PCNA-monoubiquitylation constitutes a pre-
dominant pathway for the rescue of stalled replication
forks, and, similarly, human Rad18 is required for the post-
replication repair of UV-damaged DNA (41). Independent
laboratories have also reported thatRAD18 and SPARTAN
cooperate in the protection against UV-irradiation though
the role of Rad18 in regulating Spartan’s function is still
contradictory. To address whether Spartan cooperates with
Rad18 in DPC repair, we carried out epistasis analysis com-
paring the phenotypes of single Spartan- and Rad18- and
double Spartan/Rad18-silenced cell lines employing three
different assays, namely, cell survival, DPC-specific BrdU
comet assay and theDNAfibre analysis (Figure 5). First, we
confirmed the efficiency of silencing and, for complementa-
tion studies, the expression of FLAG-Spartan and FLAG-
Rad18 from vectors resistant to shRNA silencing by West-
ern blot analysis (Supplementary Figure S3A and B).When
comparing the FA sensitivity of the single- and double-
silenced cell lines, we observed that the Spartan/Rad18-
silenced cells did not exhibit higher FA sensitivity than
the Spartan-silenced or the Rad18-silenced cells, indicat-
ing that Spartan and Rad18 act together in protecting cells
from FA-induced damage. To further confirm the epistatic
relationship between SPARTAN and RAD18, we tested
whether ectopic expression of the siRNA-resistant Spar-
tan or Rad18 proteins can rescue the observed phenotype.
While the expression of Spartan in Spartan-silenced cells
and the expression of Rad18 in Rad18-silenced cells could
fully rescue FA sensitivity, the expression of either Spar-
tan or Rad18 alone could not rescue the sensitivity of the
Spartan/Rad18 double-silenced cells. However, expression
of Spartan and Rad18 together readily rescued the sensi-
tivity of Spartan/Rad18-silenced cells, supporting further
that their cooperation is required to achieve DPC resistance
(Figure 5A).
We also employed the comet assay to reveal the func-
tional interplay of Spartan and Rad18. We found that
the DPC-repair deficiency of the shSPARTAN/shRAD18
double-silenced cell line was not higher than that of the
shRAD18 cell line, indicating again the requirement for
their interaction (Figure 5B, C and Supplementary Figure
S3C). Interestingly, the deficiency of shRAD18 was higher
than that of shSPARTAN, suggesting that elimination of
the RAD6-RAD18 pathway affects not only the Spartan-
dependent DPC-repair pathway but other, yet to be identi-
fied DPC-repair pathways as well.
Finally, we tested for interaction between Spartan and
Rad18 in the immediate bypass of FA-induced lesions
via the DNA fibre assay (Figure 5D), dot-plotting the
results (Figure 5E) where every dot represents a single
fibre. We also calculated the mean of replication track
lengths under unchallenged conditions as well as after
FA exposure (shown by horizontal blue lines in Figure
5E). Comparison revealed a slower replication fork move-
ment after FA treatment in the shSPARTAN, shRAD18
and shSPARTAN/shRAD18 cells than in the control shC-
TRL cells. Importantly, fork slowdown was not addi-
tive when Spartan and Rad18 silencing was combined in
shSPARTAN/shRAD18 cells, indicating that Rad18 and
Spartan function together in lesion bypass of FA-induced
DNA damage (Figure 5F and Supplementary Figure S3D).
Taken together, all three independent methods confirmed
an epistatic relationship between SPARTAN andRAD18 in
providing cellular resistance against DPC.
DISCUSSION
DPCs are toxic lesions that are heterogeneous in size and
origin and interfere with most of the enzymatic processes
that take place on the DNA such as replication and tran-
scription. For a long time, the repair of DPCs was believed
to be carried out only by canonical repair pathways such
as nucleotide excision repair, the Fanconi anaemia pathway
and homologous recombination (9,53). In contrast to this
general view, a so far hidden DNA repair mechanism has
been recognized recently in yeast with the finding that yeast
Wss1 has a protease activity directly eliminating the pro-
tein components of DPCs (32), and a replication-dependent
proteolysis mechanism acting on DPC, which was reca-
pitulated using Xenopus egg extract in vitro (54), has also
been described. In our study, we investigated whether hu-
man cells exhibit similar repair mechanisms. The presence
of a metalloprotease-like domain in Spartan and its domain
structure suggested some similarity to yeast Wss1; how-
ever, the questions whether Spartan has a protease activity,
whether it facilitates DPC repair, and whether a yet unrec-
ognized direct mechanism exists in human cells for DPC re-
pair have not been addressed.
Here, we show that human Spartan is required for fa-
cilitating DPC-repair and replication of DPC-containing
DNAand that it acts together with theRAD6-RAD18DDT
pathway. We are the first to report that purified Spartan
has a DNA-dependent protease activity degrading certain
proteins bound to DNA. In concert, our in vivo findings re-
veal that Spartan deficiency causes a slower DPC removal
and that Spartan’s protease- orDNA-binding deficiency im-
pairs highly the DPC-repair of replicating cells as detected
by aDPC-specific alkaline BrdU comet assay.Moreover, we
demonstrate, employing the DNA fibre method, that Spar-
tan deficiency dramatically decreases the speed of replica-
tion forks under FA-induced replication stress, indicating a
role for Spartan in the immediate replication ofDPCderiva-
tives. Our results are fully consistent with the findings on
the protease activity of Spartan and its role in DPC-repair
published very recently at the final stage of the revision of
our paper (55–57). In addition to these results, we provide
genetic evidence for the interaction of SPARTAN with the
RAD6-RAD18 DDT pathway in DPC repair.
Based on our results, we propose a model shown in Fig-
ure 6 for the function of the protease Spartan in the com-
pletion of the replication ofDPC-containingDNA.We sug-
gest that when replication stalls upon encountering a DPC,
Spartan can gain access to the fork, where its newly dis-
covered DNA-dependent protease activity can remove the
protein part of the DPC thereby facilitating the completion
of replication. If the protein was bound covalently to the
DNA, a short peptide derivative remains on the DNA the
subsequent bypass of which may require translesion poly-
merase or template switching. Previous studies suggested
that Spartan can facilitate the recruitment of the transle-
sion synthesis polymerase (21,22,24,48) to the stalled fork,
thus, it is possible that Spartan can perform multiple tasks
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Figure 5. Spartan and Rad18 act together in protecting genome integrity from FA-induced genotoxic stress. (A) Epistasis analysis of SPARTAN and
RAD18 using cell viability assay for FA treatment. HEK 293 cells stably expressing shRNAs of SPARTAN,RAD18 andRAD18/SPARTAN or control were
transfected with empty vector orN-terminally Flag-tagged SPARTAN,RAD18 or SPARTAN-RAD18 siRNA-resistant plasmid constructs. After 48 h, cells
were treated with FA, and after 7 days of treatment cell viability was determined. (B) SPARTAN and RAD18 show epistatic relationship in DPC-removal.
Representative images of the epistasis analysis of SPARTAN and RAD18 performed with the BrdU comet assay. The indicated cell lines were treated with
500 MFA. (C) Quantitation of the experiment shown in (B). Statistical analysis was made by Student’s t-test. Statistical significance was labelled by ***:
P < 0.001, NS: not significant. (D) SPARTAN and RAD18 show epistatic relationship in the replication of DPC-containing DNA. Representative images
of fibres from Spartan, Rad18 and Rad18/Spartan shRNA-silenced cells treated with FA or left untreated. (E) Quantitative measurements of second track
shortening after FA treatment of different depleted cell lines, detected in the fibre assay detailed in (D), are illustrated in a dot plot diagram. Each dot
represents a single measurement of the second label of a single ongoing replication fork. Three independent experiments were carried out, and at least
100 fibres per experiment per cell line were measured. Horizontal lines indicate mean values. (F) Relative replication fork speed was calculated from the
quantitative measurements of the fibre assay detailed in (D) for Spartan-, Rad18- and Spartan/Rad18-depleted cells.
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Figure 6. Model for the role of the Spartan protease in the replication of DPC-containing DNA. Stalling of the helicase on the leading strand and the
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the stalled monoubiquitylated PCNA and the exposed ssDNA attract Spartan, which simultaneously binds Ub-PCNA through its UBZ and PIP domains
and ssDNA through its DNA-binding domain. The binding of ssDNA results in the conformational change of Spartan, which in turn activates Spartan’s
protease activity. The protease Spartan can cleave the DPC leaving free DNA or, if the protein was covalently bound, a short peptide bound to the DNA.
Spartan’s activity may also facilitate polymerase exchange somehow, for example, by removing some subunits of the replication complex and thus giving
access to a TLS polymerase, which can then bypass the remaining short peptide-DNA crosslink adduct. These events might happen immediately when the
fork stalls at a DPC or occur only after the majority of the DNA has replicated during the so-called post-replicative repair process. Since the replicative
helicase might be inhibited only on the leading strand by a DPC, on the lagging strand the proteolytic cleavage of the DPC by Spartan may leave short
peptides bound to the DNA that are accessible to immediate bypass by TLS polymerases and can be investigated by the DNA fibre assay.
at DPCs and, in addition to the digestion of DPCs it can fa-
cilitate the exchange of the replicative polymerase to a dam-
age bypass player. In doing so, the Spartan protease may re-
move some components of the replication machinery such
as the catalytic subunit of the replicative polymerase thus
providing access for a TLS polymerase to the remaining
subunits of the replication machinery containing ubiquitin-
PCNA. Previous studies also indicate that Spartan interacts
with and recruits the ubiquitin-selective chaperone p97 to
the blocked replication fork (25,26); thus, it would be inter-
esting to study whether p97 is required for DPC-repair, and,
if so, whether it acts together with Spartan in the proteolytic
step by restructuring the substrates for proteolytic cleavage
and removing the proteolytic products.
Timely activation and targeting of the protease activity
of Spartan must be particularly important since it should
remove only DPCs or particular components of the repli-
cation machinery but keep the various protein components
of the replication machinery intact so that they are able
to resume replication after bypass. Our biochemical stud-
ies provided a few hints when we tested certain replication
complex components as potential substrates and found that
Spartan did not cleave PCNA, ubiquitin-PCNA, RFC and
RPA, rather, RFC and RPA inhibited the protease activity
of Spartan, most probably by outcompeting its binding to
the DNA. Thus, successful competition for ssDNA binding
might be a rate limiting step for Spartan activation, and one
can envision that certain Spartan-interacting proteins such
as ubiquitin–PCNA or the p97 chaperone may facilitate its
successful competition with other ssDNA-binding proteins.
Some of the current models suggest that the exposed ss-
DNA at stalled replication forks becomes rapidly covered
by RPA (58), signalling for Rad18-dependent PCNA ubiq-
uitylation, which then provides a binding surface for Spar-
tan recruitment. Thus, it is possible that Spartan becomes
activated upon binding to ubiquitin-PCNA by its PIP and
UBZ domains, in the vicinity of which––at the stalled repli-
cation fork––protein free ssDNA becomes available, and
Spartan cleaves only the DPCs neighbouring these ssDNA
regions.
DPCs can be formed during normal enzymatic reactions
involving transient covalent linkage between the enzyme
and the DNA such as when topoisomerase 1 nicks one
strand of the DNA to relieve DNA torsional stress, and for
some of these special DPCs a dedicated repair pathway ex-
ist; e.g. DNA-trapped topoisomerase 1 is repaired by TDP1
cleaving the protein–DNA binding (59). In addition, reac-
tive agents like aldehydes, UV, certain metal ions, and radi-
ation can potentially crosslink any protein operating on the
DNA (60); the repair of these requires a more general re-
pair mechanism. Besides exogenous exposure, many agents
are generated endogenously, in particular FAduring histone
demethylation (34). The importance of endogenously pro-
duced aldehyde was revealed by the finding that in mice the
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lack of aldehyde-detoxifying enzymes causes anaemia and
leukaemia when the Fanconi anaemia pathway is not func-
tional (61). In human blood, the normal endogenous FA
concentration is as high as 100 M (36). Furthermore, FA
concentration in the metabolically active liver of rats was
reported to be 2- to 4-fold higher than that found in the
blood (62). Thus, DPC repair can be particularly impor-
tant in liver, which might explain why the familial SPAR-
TAN mutation specifically leads to early onset hepatocel-
lular carcinoma. In addition, SPARTAN mutant patients
were also affected by a progeroid syndrome characterized
by genomic instability (29). Spartan insufficiency in trans-
genic mice also causes chromosomal instability and early
onset of age-related phenotypes (28). It is of particular im-
portance that mutations of the active site of the metallo-
protease SprT domain of mouse Spartan impaired both le-
sion bypass and cell viability while the phenotypes of mu-
tations in other domains of Spartan, such as in the SHP-
domain mediating its interaction with the p97 chaperone,
were not so prominent (28). In accordance with these find-
ings, our complementation assay performed by monitoring
FA-inducedDPC-repair and using Spartan proteinsmutant
in the active site of the metalloprotease domain or in the
DNA-binding site suggested a role for the protease activ-
ity of Spartan in the completion of replication. Also, sim-
ilarly to the observations in mice, we found that Spartan-
deficient human cells leave the S phase containing abnor-
mal replication intermediates such as chromatin bridges, re-
flecting unresolved replication, which may explain Spartan
deficiency-caused genomic instability. These findings are in
good agreement with the clastogenic effect of FA reported
formerly; SCE elevation with simultaneous micronucleus
formation parallel to DPC induction was observed (43).
The recently described DNA-dependent metalloprotease
Wss1 represents a DPC-specific pathway that is indepen-
dent from NER and homologous recombination, as de-
tected by epistasis analysis using rad4Δ NER-deficient and
rad52Δ homologous recombination-deficient strains. Based
on our results, it would be interesting to explore the epistatic
relationship between WSS1 and RAD18 and Ubiquitin-
PCNA as well. This might require a more specific pheno-
type than cell survival, with a more specialized assay that is
able to visualize events at the stalled replication fork such
as the DNA fibre analysis or the BrdU comet assay we em-
ployed.
We anticipate our results on the protease Spartan to be
a starting point for more sophisticated assays on the exis-
tence of a direct DPC repair pathway in human cells. For
example, the involvement and the functions of Spartan-
interacting partners such as ubiquitylated-PCNA, Rad18
and chaperon p97 in DPC repair and the connection of this
direct repair pathway with other repair pathways operat-
ing in the S phase, in particular homologous recombina-
tion, can now be tested. Also, it opens the way to in vitro
assays aiming to reconstitute DPC repair with site-specific
covalent DPC substrates and purified proteins and to exam-
ining specific elementary steps such as Spartan activation
on RPA-covered DNA, the modifying effect of ubiquitin–
PCNA binding, how Spartan is kept under control to avoid
unwanted proteolysis, and Spartan-mediated exchange of
replicative and translesion synthesis polymerases at DPCs
and their derivatives. Finally, it will be interesting to explore
the level to which the DPC repair function of Spartan con-
tributes to protection against hepatocellular carcinoma and
progeroid diseases.
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